SynthesisAnti-cancer agents in medicinal chemistry2026
The Role of Artemisinin and its Derivatives in Cancer Therapy via Ferroptosis: A Systematic Review of
Synthesis in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionArtemisinin (ART), a sesquiterpene lactone derived from Artemisia annua L., and its semisynthetic derivatives such as dihydroartemisinin (DHA) and artesunate (ARTE) have gained significant attention for their anticancer potential beyond their established antimalarial effects. The antitumor activity is mediated by various mechanisms, with ferroptosis-an iron-dependent, non-apoptotic form of cell death characterized by lipid peroxidation- standing out as a key pathway. Recent in vitro, in vivo, and in silico studies suggest that artemisinin compounds can trigger ferroptosis in various cancers, including breast, liver, pancreatic, and glioma, by disrupting iron homeostasis, inhibiting glutathione peroxidase 4 (GPX4), and increasing reactive oxygen species (ROS) accumulation.
methodsA comprehensive literature search was conducted up to 2025 using relevant keywords related to artemisinin, cancer, and ferroptosis in databases such as PubMed, Web of Science, and Scopus.
resultsExperimental studies demonstrate that dihydroartemisinin and artesunate elevate intracellular Fe² levels and promote ROS-mediated lipid peroxidation. Animal models further validate these effects, showing tumor growth suppression with minimal systemic toxicity. In silico analyses support these findings, revealing interactions between artemisinin derivatives and ferroptosis-related proteins like GPX4 and transferrin receptor 1 (TfR1). DISCUSSION: The findings collectively indicate that artemisinin and its derivatives induce ferroptosis through irondependent ROS accumulation and GPX4 inhibition, positioning ferroptosis as a central mechanism underlying their anticancer activity.
conclusionThis review analyzed 66 original research articles and identified ferroptosis as the primary mechanism by which artemisinin and its derivatives exert anticancer effects, often in combination with apoptosis, autophagy, or cell cycle arrest. In silico studies confirm strong interactions with ferroptosis-related targets. Lung and liver cancers emerged as the most frequently studied and responsive, highlighting them as key targets for future translational efforts. Standardized methodologies are needed to improve reproducibility and clinical relevance.
Indexed as
Identifiers
41833023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.